Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.

Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H.

J Clin Oncol. 2013 Jul 10;31(20):2548-53. doi: 10.1200/JCO.2012.44.6823. Epub 2013 Jun 3.

2.

A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome.

Jeong SH, Kim YJ, Lee JH, Kim YK, Kim SJ, Park SK, Do YR, Kim I, Mun YC, Kim HG, Lee WS, Yi HG, Joo YD, Choi CW, Kim SR, Na SM, Jang JH.

Oncotarget. 2015 Dec 29;6(42):44985-94. doi: 10.18632/oncotarget.6242.

3.

Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study.

Wu D, Du X, Jin J, Xiao Z, Shen Z, Shao Z, Li X, Huang X, Liu T, Yu L, Li J, Chen B, He G, Cai Z, Liang H, Li J, Ruan C.

Adv Ther. 2015 Nov;32(11):1140-59. doi: 10.1007/s12325-015-0263-8. Epub 2015 Nov 14.

4.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C.

J Clin Oncol. 2012 Jul 20;30(21):2670-7. doi: 10.1200/JCO.2011.38.9429. Epub 2012 Jun 11.

5.

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.

Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP.

Cancer. 2007 Jan 15;109(2):265-73.

6.

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A.

Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1.

PMID:
28870615
7.

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H.

J Clin Oncol. 2009 Aug 10;27(23):3842-8. doi: 10.1200/JCO.2008.19.6550. Epub 2009 Jun 15.

8.

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.

Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ.

Lancet Oncol. 2017 Oct;18(10):1317-1326. doi: 10.1016/S1470-2045(17)30576-4. Epub 2017 Aug 24.

PMID:
28844816
9.

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.

J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.

PMID:
21483003
10.

Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis.

Li X, Song Q, Chen Y, Chang C, Wu D, Wu L, Su J, Zhang X, Zhou L, Song L, Zhang Z, Xu F, Hou M.

PLoS One. 2014 Apr 18;9(4):e95473. doi: 10.1371/journal.pone.0095473. eCollection 2014.

11.

Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.

Iastrebner M, Jang JH, Nucifora E, Kim K, Sackmann F, Kim DH, Orlando S, Jung CW, Basquiera A, Klein G, Santini F, Bernard HI, Korin J, Taborda G.

Leuk Lymphoma. 2010 Dec;51(12):2250-7. doi: 10.3109/10428194.2010.524324. Epub 2010 Oct 7.

PMID:
20929328
12.

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H.

Cancer. 2006 Apr 15;106(8):1794-803.

13.

Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan.

Oki Y, Kondo Y, Yamamoto K, Ogura M, Kasai M, Kobayashi Y, Watanabe T, Uike N, Ohyashiki K, Okamoto S, Ohnishi K, Tomita A, Miyazaki Y, Tohyama K, Mukai HY, Hotta T, Tomonaga M.

Cancer Sci. 2012 Oct;103(10):1839-47. doi: 10.1111/j.1349-7006.2012.02386.x. Epub 2012 Sep 14.

14.

Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.

Wu W, Lin Y, Xiang L, Dong W, Hua X, Ling Y, Li H, Yan F, Xie X, Gu W.

Ann Hematol. 2016 Jun;95(7):1051-7. doi: 10.1007/s00277-016-2681-3. Epub 2016 Apr 26.

PMID:
27116384
15.

Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.

Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E.

Clin Ther. 2010 Dec;32(14):2444-56. doi: 10.1016/j.clinthera.2010.12.003.

PMID:
21353113
16.

Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.

Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S289-94. doi: 10.1016/j.clml.2013.05.025. Epub 2013 Aug 19.

17.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP.

Blood. 2007 Jan 1;109(1):52-7. Epub 2006 Aug 1.

18.

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A.

J Clin Oncol. 2000 Mar;18(5):956-62.

PMID:
10694544
19.

A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome.

Lee JH, Jang JH, Park J, Park S, Joo YD, Kim YK, Kim HG, Choi CW, Kim SH, Park SK, Park E, Min YH.

Haematologica. 2011 Oct;96(10):1441-7. doi: 10.3324/haematol.2011.046078. Epub 2011 Jun 9.

20.

[Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].

Klepfish A, Silbershatz I, Lugassy G, Shimoni A, Mittelman M.

Harefuah. 2013 Oct;152(10):591-4, 624. Hebrew.

PMID:
24450031

Supplemental Content

Support Center